Sugi Predict

Sugi Predict / Compounds / SCHEMBL710274

SCHEMBL710274

SCHEMBL710274

Fc1ccccc1COc1cc(OCc2ccccc2F)cc(-c2nc3cccnc3[nH]2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP1B1 Q16678 1/20 0.45
▸ EGFR P00533 2/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ SMO Q99835 1/20 0.40
▸ PARP15 Q460N3 2/20 0.39
▸ PARP10 Q53GL7 2/20 0.39
▸ RARA P10276 1/20 0.39
▸ RARB P10826 1/20 0.39
▸ RARG P13631 1/20 0.39
▸ GCK P35557 1/20 0.39
▸ MAOB P27338 6/20 0.39
▸ DHFR P00374 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2668247 0.95 CYP1A1 (0.44) CYP1A1CYP1A2CYP1B1EGFRPRMT5
SCHEMBL710663 0.94 CYP1A1 (0.41) CYP1A1CYP1A2CYP1B1EGFRPRMT5
SCHEMBL2656031 0.90 CYP1A1 (0.39) CYP1A1CYP1A2CYP1B1EGFRPRMT5
SCHEMBL710161 0.88 CYP1A1 (0.38) CYP1A1CYP1A2CYP1B1EGFRPRMT5
Trifluoroacetic Acid SCHEMBL711105 0.88 CYP1A1 (0.41) CYP1A1CYP1A2CYP1B1PRMT5SMO
SCHEMBL709552 0.88 GCK (0.38) CYP1A1CYP1A2CYP1B1EGFRPRMT5
SCHEMBL2085435 0.88 GCK (0.38) CYP1A1CYP1A2CYP1B1EGFRPRMT5
SCHEMBL709551 0.88 GCK (0.38) CYP1A1CYP1A2CYP1B1EGFRPRMT5
Trifluoroacetic Acid SCHEMBL709930 0.85 GCK (0.48) CYP1A1CYP1A2CYP1B1SMORARA
SCHEMBL10206641 0.83 PRMT5 (0.51) PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 — — EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK CYP1A1 1205/4885CYP1A2 937/4885CYP1B1 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.